
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Contemporary Pediatrics' 2008 Media Information -- our numbers aren't kid's play. Practical information for today's pediatrician + increased sales for your product






